Wockhardt urgently needs Rs 400 crore and its two wonder drugs
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
February 07, 2024•8 min
0
February 07, 2024•8 min
0
More in Business
Business
Can Meesho’s value-commerce playbook pass the IPO test?
The ecommerce platform will be hard-pressed to justify its estimated $7-8 billion valuation—up nearly 2x from just 10 months ago—at a time of ho-hum growth and flagging profitability.
You may also like
Business
Laurus Labs is Indian pharma’s dark horse
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
Business
Has Aurobindo Pharma left its wild swings behind?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
Business
Is Mankind Indian pharma’s next big star?
From making condoms to steering clear of costly formulations, the drugmaker’s strategy of taking the road less travelled could now give it a seat at the high table.